Prevalence of Helicobacter pylori antibodies in long-term dialysis patients

Nephrology (Carlton). 2004 Apr;9(2):73-6. doi: 10.1111/j.1440-1797.2004.00239.x.

Abstract

Background: Helicobacter pylori has been reported to play an important role in the development of gastritis and gastric ulcer.

Methods: This study included 168 patients with end-stage renal disease (ESRD; 30 non-dialysis patients, 138 patients receiving dialysis; mean duration of dialysis: 57.3 +/- 61.7 months) and 138 control volunteers. We investigated the prevalence of H. pylori infection by measuring H. pylori antibody (IgG) levels.

Results: The prevalence of H. pylori infection was 62.3% in the control group, 53.3% in the non-dialysis patients, and 36.9% in the dialysis patients. The percentage decreased with a reduction of renal function. In addition, the proportion of H. pylori-positive patients decreased with the duration of dialysis, and the antibody titre was also significantly decreased. There was no association between long-term oral administration of H2RA (H2 receptor antagonist) and the incidence of H. pylori infection.

Conclusion: Among dialysis patients, the proportion of H. pylori-positive patients was low. An aetiological factor other than H2RA agents was suggested. Renal failure or dialysis treatment may influence H. pylori infection.

MeSH terms

  • Adult
  • Age Factors
  • Aged
  • Antibodies, Bacterial / blood*
  • Female
  • Helicobacter pylori / immunology*
  • Histamine H2 Antagonists / pharmacology
  • Humans
  • Male
  • Middle Aged
  • Renal Dialysis*
  • Time Factors

Substances

  • Antibodies, Bacterial
  • Histamine H2 Antagonists